Breast Cancer Treatments: Updates and New Challenges
Autor: | Francine Durocher, Anna Burguin, Caroline Diorio |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Medicine (miscellaneous) Estrogen receptor personalized therapies Review Disease Breast cancer breast cancer Internal medicine HER2 Progesterone receptor medicine Adverse effect luminal molecular subtypes business.industry Cancer Immunotherapy medicine.disease Radiation therapy breast cancer treatment Medicine business TNBC |
Zdroj: | Journal of Personalized Medicine, Vol 11, Iss 808, p 808 (2021) Journal of Personalized Medicine |
ISSN: | 2075-4426 |
Popis: | Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B, HER2 and triple-negative breast cancer (TNBC)) according to the expression of the estrogen receptor (ER) and the progesterone receptor (PR), and the overexpression of the human epidermal growth factor receptor 2 (HER2). Current BC treatments target these receptors (endocrine and anti-HER2 therapies) as a personalized treatment. Along with chemotherapy and radiotherapy, these therapies can have severe adverse effects and patients can develop resistance to these agents. Moreover, TNBC do not have standardized treatments. Hence, a deeper understanding of the development of new treatments that are more specific and effective in treating each BC subgroup is key. New approaches have recently emerged such as immunotherapy, conjugated antibodies, and targeting other metabolic pathways. This review summarizes current BC treatments and explores the new treatment strategies from a personalized therapy perspective and the resulting challenges. |
Databáze: | OpenAIRE |
Externí odkaz: |